Alevin Therapeutics Ltd
Development of safe and effective medicines for patients with life-threatening diseases through integrin inhibition
Development of safe and effective medicines for patients with life-threatening diseases through integrin inhibition
Alevin Therapeutics, a biotechnology company founded in 2022, is dedicated to the development of safe and effective medicines for patients with life-threatening diseases through integrin inhibition. Focusing on integrin inhibitors as novel treatments for fibrotic diseases, particularly Idiopathic Pulmonary Fibrosis, Alevin Therapeutics has garnered attention for its innovative approach in the biotechnology industry. The company received its last investment in a Seed Round at 29 July 2022, with participation from o2h Ventures and the University of Nottingham. Based in the United Kingdom, Alevin Therapeutics has positioned itself as an emerging player in the biotechnology space with its promising focus on integrin inhibition to address critical medical needs.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 2 |
|
29 Jul 2022 |
No recent news or press coverage available for Alevin Therapeutics Ltd.
We care about your data, and we'd love to use cookies make your experience better.
